Guidant, Medtronic Look To CHF Market To Offset Slowing Of Stent Growth
This article was originally published in The Gray Sheet
Executive Summary
Seeing the initial signs of declining stent prices and an uninspiring tachycardia product line-up, investors bypassed 1998's device darlings in 1999 - Medtronic and Guidant - while keeping a close eye on efforts by those companies to develop a potentially lucrative market opportunity in treating congestive heart failure (CHF) patients.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.